Retail traders showed bullish sentiment following strong Q1 revenue growth and positive clinical data for its bladder cancer drug, despite a 54% jump in short interest.
Top mid-cap stock performers last week: Foot Locker, Inc. (FL), Archer Aviation Inc. (ACHR), DigitalBridge Group, Inc. (DBRG), NuScale Power Corporation (SMR), Diginex Limited (DGNX), ImmunityBio, Inc. (IBRX), Oklo Inc. (OKLO), Intuitive Machines, Inc. (LUNR).
ImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle invasive bladder cancer (NMIBC).
HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025.
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%, down from 50.9% in January.
The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer
Explore this week's top-performing mid-cap stocks, including H&E Equipment Services' impressive 100.59% surge following an acquisition announcement by United Rentals. Discover why stocks like SEMrush and Blueprint Medicines also experienced significant gains, impacting investment portfolios positively.
